Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research  How it helps Latest publication
Litronesib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
CoV2-09
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/20/2021
S2X324
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/23/2021
Pyridone 6
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
(E)-4-(4-((5-(4,5-Dimethyl-2-nitrophenyl)furan-2-yl)Methylene)-3-Methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)benzoic acid
Potential treatment - theoretical effect Experimental Other treatment Apr/12/2021
Flumatinib
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
CoV2-26
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/20/2021
(5-Chloropyridin-3-yl) 1H-indole-4-carboxylate
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/28/2021
Kasugamycin
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/23/2021
GC376
Potential treatment - pre-clinical evidence Experimental Antiviral Apr/28/2021
S-[2-[[(2R,3S,4R,5R)-3,4-Dihydroxy-5-(2-oxo-7H-pyrrolo[2,3-d]pyrimidin-3-yl)oxolan-2-yl]methoxy-[2-(2,2-dimethylpropanoylsulfanyl)ethoxy]phosphoryl]oxyethyl] 2,2-dimethylpropanethioate
Potential treatment - theoretical effect Experimental Antiviral Feb/01/2021
3,3'-(Biphenyl-4,4'-diyldidiazene-2,1-diyl)bis(4-aminonaphthalene-1-sulfonic acid)
Potential treatment - theoretical effect Experimental Antiviral Mar/26/2021
COV2-2130
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/15/2022
N(4)-Hydroxycytidine
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/26/2022
CoV2-06
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/20/2021
5-(Acryloylamino)-2-methyl-N-[(1R)-1-(naphthalen-1-yl)ethyl]benzamide
Potential treatment - pre-clinical evidence Experimental Antiviral Feb/02/2021
mAb Beta-54
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
mAb 253
Potential treatment - pre-clinical evidence Experimental Antiviral Jan/04/2022
S2H97
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/23/2021
Pyronaridine
Potential treatment - pre-clinical evidence Experimental Antiviral Mar/10/2021